Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin

被引：0
|
作者：
Carroll B. Leevy
机构：
[1] University of Medicine & Dentistry of New Jersey,Department of Medicine, Division of Gastroenterology/Hepatology
[2] New Jersey Medical School Liver Center,undefined
来源：
Digestive Diseases and Sciences | 2008年 / 53卷 / 7期
关键词：
D O I：
10.1007/s10620-008-0252-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2009 / 2009
相关论文
共 50 条
  • [41] r-interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders
    Perasso, A
    Testino, G
    Ansaldi, F
    Venturino, V
    Icardi, GC
    HEPATOLOGY, 1999, 29 (01) : 297 - 298
  • [42] Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
    Al Ali, Jaber
    Owayed, Salem
    Al-Qabandi, Wafa'a
    Husain, Khaled
    Hasan, Fuad
    ANNALS OF HEPATOLOGY, 2010, 9 (02) : 156 - 160
  • [43] Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
    Wong, JB
    Davis, GL
    Pauker, SG
    AMERICAN JOURNAL OF MEDICINE, 2000, 108 (05): : 366 - 373
  • [44] Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy
    Chousterman, N
    Auray-Cartier, V
    Hagege, H
    Arpurt, JP
    Cassan, P
    Denis, J
    Gargot, D
    Nalet, B
    Nouel, O
    Pariente, A
    Wartelle-Bladou, C
    HEPATOLOGY, 2002, 36 (04) : 362A - 362A
  • [45] Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed interferon therapy.
    Birdi, PK
    Wustrack, S
    Rostetter, E
    King, JW
    Balart, LA
    GASTROENTEROLOGY, 2000, 118 (04) : A1426 - A1426
  • [46] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
    Carrat, F
    Bani-Sadr, F
    Pol, S
    Rosenthal, E
    Lunel-Fabiani, F
    Benzekri, A
    Morand, P
    Goujard, C
    Pialoux, G
    Piroth, L
    Salmon-Céron, D
    Degott, C
    Cacoub, P
    Perronne, C
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23): : 2839 - 2848
  • [47] Peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients
    Crespo, M
    Sauleda, S
    Esteban, JI
    Juarez, A
    Buti, M
    Pahissa, A
    Esteban, R
    Guardia, J
    HEPATOLOGY, 2005, 42 (04) : 701A - 702A
  • [48] High dose daily consensus interferon and ribavirin is an effective option in chronic hepatitis C patients who are nonresponders to PEG-Interferon and ribavirin
    Rothstein, KD
    Koka, R
    Hargrove, H
    Fernandez, A
    Singh, S
    Araya, V
    Munoz, SJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S122 - S122
  • [49] Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis C virus genotype 1: Are nonresponders and relapsers different populations?
    Silva, Giovanni Faria
    Polonio, Rodrigo Jose
    Moura Campos Pardini, Maria Ines
    Corvino, Silvia Maria
    Saccomano Henriques, Rita Maria
    Peres, Mari Nilce
    Arruda Silveira, Liciana Vaz
    Rabello Coelho, Kunie Iabuki
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (06): : 554 - 560
  • [50] Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin
    Kelly, D. A.
    Haber, B.
    Gonzalez-Peralta, R. P.
    Murray, K. F.
    Jonas, M. M.
    Molleston, J. P.
    Narkewicz, M. R.
    Sinatra, F. R.
    Lang, T.
    Lachaux, A.
    Wirth, S.
    Shelton, M.
    Te, H. S.
    Pollack, H.
    Deng, W.
    Noviello, S.
    Albrecht, J. K.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (04) : 263 - 270
12345